Anhydrous enol oxaloacetate is under clinical development by MetVital and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Anhydrous enol oxaloacetate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Anhydrous enol oxaloacetate overview
Anhydrous enol-oxaloacetate (AEO) is under development for the treatment of myasthenia gravis, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, glioblastoma multiforme, hepatocellular carcinoma and for fatigue after resolution of COVID-19 infection. It is administered through oral route as a pill or capsule. The drug candidate acts by targeting AMP-protein activated Kinase (AMPK). It was under development for the treatment of Parkinson's disease and traumatic brain injury.
MetVital overview
MetVital is a biopharmaceutical company developing small molecule modulators to improve cellular metabolism. Its lead product candidate AEO (Anhydrous Enol-Oxaloacetate), a patented small molecule reduces glutamate level and protects the brain from excitotoxicity, a condition that kills brain cells. The company is advancing AEO development against glioblastoma multiforme, Alzheimer’s disease, Amyotrophic Lateral Sclerosis (ALS), breast cancer, hepatocellular carcinoma and other brain conditions. MetVital is headquartered in San Diego, California, the US.
For a complete picture of Anhydrous enol oxaloacetate’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
